The first clinical dosing of a TRPML1 agonist places the autophagy–lysosomal pathway on the map as a tractable target in neurodegenerative disease, a biological thesis that has long carried genetic support but lacked a clinical-stage molecule. Lysoway Therapeutics, a Cambridge, Massachusetts-based biotechnology company, announced on May 11, 2026 that the first participant was dosed on May 5 in its Phase I trial of LW-1017, a brain-penetrant small-molecule TRPML1 agonist intended for Alzheimer's disease and Parkinson's disease. The study is being conducted in Melbourne, Australia, and is enrolling healthy volunteers across single ascending dose and multiple ascending dose cohorts to evaluate safety, tolerability, and pharmacokinetics. No trial end date, enrollment target, or registered trial identifier was disclosed in the announcement.
Research context
TRPML1 is a lysosomal calcium channel that regulates autophagic flux and lysosomal membrane integrity. Impaired autophagy–lysosomal function has been implicated in both amyloid and tau accumulation in Alzheimer's disease and in alpha-synuclein aggregation in Parkinson's disease, positioning the pathway as an upstream point of intervention rather than a downstream consequence of pathology. Published work has shown that TRPML1 loss can trigger cathepsin B–dependent apoptosis, lending mechanistic weight to the agonist hypothesis. The challenge historically has been achieving the combination of brain penetrance, oral bioavailability, potency, and selectivity required for a viable CNS small molecule — a constraint Lysoway claims to have addressed through structure-guided discovery and cryo-EM-based platform design.
Alzheimer's disease treatment has shifted materially since 2023, with lecanemab (Leqembi, Eisai and Biogen) receiving traditional US FDA approval in July 2023 and donanemab (Kisunla, Eli Lilly) following in July 2024. Both are anti-amyloid monoclonal antibodies restricted to early symptomatic disease with confirmed amyloid pathology, administered by IV infusion, and associated with amyloid-related imaging abnormalities that limit use in certain genotypes. Parkinson's disease has seen only symptomatic advances, including subcutaneous levodopa delivery with foscarbidopa/foslevodopa (Vyalev, AbbVie) approved in late 2024. No disease-modifying therapy has been approved for Parkinson's disease. The autophagy–lysosomal pathway remains entirely unexploited clinically in either indication, which is the mechanistic space LW-1017 is designed to occupy.
Competitive landscape
No other TRPML1 agonist has been identified in active clinical development based on available evidence, which is consistent with Lysoway's claim that LW-1017 is the first in its class to reach the clinic. Other companies are set to follow in Lysoway's path, with US-based biotech Casma Therapeutics last year revealing it had nominated a TRPML1 agonist and would seek IND approval.